IL317573A - Combination therapy for treating cancer - Google Patents
Combination therapy for treating cancerInfo
- Publication number
- IL317573A IL317573A IL317573A IL31757324A IL317573A IL 317573 A IL317573 A IL 317573A IL 317573 A IL317573 A IL 317573A IL 31757324 A IL31757324 A IL 31757324A IL 317573 A IL317573 A IL 317573A
- Authority
- IL
- Israel
- Prior art keywords
- combination therapy
- treating cancer
- cancer
- treating
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263366407P | 2022-06-15 | 2022-06-15 | |
| US202263386966P | 2022-12-12 | 2022-12-12 | |
| PCT/EP2023/066018 WO2023242302A1 (en) | 2022-06-15 | 2023-06-14 | Combination therapy for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317573A true IL317573A (en) | 2025-02-01 |
Family
ID=86903948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317573A IL317573A (en) | 2022-06-15 | 2023-06-14 | Combination therapy for treating cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250352539A1 (en) |
| EP (1) | EP4539847A1 (en) |
| JP (1) | JP2025522390A (en) |
| KR (1) | KR20250023494A (en) |
| CN (1) | CN119317434A (en) |
| AU (1) | AU2023290506A1 (en) |
| CA (1) | CA3258066A1 (en) |
| IL (1) | IL317573A (en) |
| MX (1) | MX2024014940A (en) |
| TW (1) | TW202415376A (en) |
| WO (1) | WO2023242302A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240325384A1 (en) * | 2023-03-31 | 2024-10-03 | Astrazeneca Ab | Dosing regimen |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0699754B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Method for diagnosing a predisposition for breast and ovarian cancer |
| DE69521002T3 (en) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutations of the 17q associated ovarian and breast cancer susceptibility gene |
| PL3354650T3 (en) | 2008-12-19 | 2022-06-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| TWI499418B (en) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | Isoquinolin-1(2h)-one derivatives |
| WO2011006794A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors |
| WO2011006803A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
| SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl compounds for use as ATR inhibitors |
| WO2013014038A1 (en) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| EP2788328B1 (en) | 2011-11-25 | 2018-01-31 | Nerviano Medical Sciences S.r.l. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| EA028506B1 (en) | 2012-10-26 | 2017-11-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors, process for the preparation and use thereof |
| TWI656121B (en) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(morpholin-4-yl)-1,7-naphthyridine |
| BR112017007708B8 (en) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Macrocyclic compound and pharmaceutical composition |
| GB201800733D0 (en) * | 2018-01-17 | 2018-02-28 | Cambridge Entpr Ltd | Cancer |
| CA3122182A1 (en) | 2018-12-18 | 2020-06-25 | Astrazeneca Ab | Pharmaceutical process and intermediates |
| TWI837403B (en) | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | Chemical compounds |
| RS66523B1 (en) | 2019-08-06 | 2025-03-31 | Wuxi Biocity Biopharmaceutics Co Ltd | Crystalline forms of an atr inhibitor and use thereof |
| IL293810A (en) * | 2019-12-11 | 2022-08-01 | Repare Therapeutics Inc | Use of atr inhibitors in combination with parp inhibitors |
| CN113797341B (en) * | 2020-06-12 | 2022-11-11 | 周凌云 | Application of ATR (attenuated total tumor) inhibitor and PARP1 inhibitor in preparation of medicines for treating hepatitis B related liver cancer |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| JP2024522736A (en) * | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | Use of ATR inhibitors in combination with PARP inhibitors for the treatment of cancer - Patents.com |
-
2023
- 2023-06-14 KR KR1020257000854A patent/KR20250023494A/en active Pending
- 2023-06-14 WO PCT/EP2023/066018 patent/WO2023242302A1/en not_active Ceased
- 2023-06-14 CA CA3258066A patent/CA3258066A1/en active Pending
- 2023-06-14 CN CN202380044783.0A patent/CN119317434A/en active Pending
- 2023-06-14 JP JP2024572481A patent/JP2025522390A/en active Pending
- 2023-06-14 EP EP23733285.3A patent/EP4539847A1/en active Pending
- 2023-06-14 AU AU2023290506A patent/AU2023290506A1/en active Pending
- 2023-06-14 IL IL317573A patent/IL317573A/en unknown
- 2023-06-14 US US18/870,743 patent/US20250352539A1/en active Pending
- 2023-06-15 TW TW112122317A patent/TW202415376A/en unknown
-
2024
- 2024-12-02 MX MX2024014940A patent/MX2024014940A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119317434A (en) | 2025-01-14 |
| AU2023290506A1 (en) | 2025-01-23 |
| MX2024014940A (en) | 2025-01-09 |
| KR20250023494A (en) | 2025-02-18 |
| US20250352539A1 (en) | 2025-11-20 |
| WO2023242302A1 (en) | 2023-12-21 |
| EP4539847A1 (en) | 2025-04-23 |
| CA3258066A1 (en) | 2023-12-21 |
| TW202415376A (en) | 2024-04-16 |
| JP2025522390A (en) | 2025-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304275A (en) | Methods for treating cancer | |
| HUE069249T2 (en) | Combination therapy for treating cancer | |
| IL307964A (en) | Combination therapy for cancer treatment | |
| IL320332A (en) | Methods for treating cancer | |
| ZA202310076B (en) | Combination therapies for treating cancer | |
| IL319513A (en) | Compounds for treating cancer | |
| IL316016A (en) | Combination therapy for treating cancer | |
| IL316017A (en) | Combination therapy for treating cancer | |
| EP3813854A4 (en) | In vivo controlled combination therapy for treatment of cancer | |
| IL316019A (en) | Combination therapy for treating cancer | |
| GB202301902D0 (en) | Combination therapy for cancer | |
| IL288178A (en) | Gmci and ddri combination therapy for treating cancer | |
| GB202218395D0 (en) | Cancer therapy | |
| EP4313029A4 (en) | Combination therapy for cancer treatment | |
| IL305777A (en) | Therapeutic combination for treating cancer | |
| IL326216A (en) | Combination therapy for prostate cancer | |
| CA3272243A1 (en) | Combination therapy for treating cancer | |
| HK40121856A (en) | Combination therapy for treating cancer | |
| HK40121918A (en) | Combination therapy for treating cancer | |
| GB202208893D0 (en) | Combination therapy for cancer | |
| IL317472A (en) | Eravacycline for treating cancer | |
| HK40107047A (en) | Therapeutic combination for treating cancer | |
| IL320482A (en) | Combination therapy for the treatment of cancer | |
| GB202508616D0 (en) | Combination therapy for cancer | |
| CA3302004A1 (en) | Combination therapy for treating prostate cancer |